Multiple sclerosis and related disorders · 2026
Divergent comorbidity profiles in neuromyelitis optica spectrum disorder and multiple sclerosis: A large single-centre cohort from Turkey.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaya Ergi, Caliskan Can, Abasıyanık Zuhal, Simsek Yasemin, Ozakbas Serkan
Аннотация
BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) are immune-mediated demyelinating disorders with overlapping clinical features. Comorbidities may influence diagnostic accuracy, therapeutic decisions, and long-term prognosis. Comparative data on comorbidity profiles in NMOSD versus MS are scarce, particularly from Middle Eastern and Mediterranean cohorts.
OBJECTIVE: To compare the prevalence and distribution of systemic, metabolic, cardiovascular, and neuropsychiatric comorbidities in patients with NMOSD and MS.
METHODS: We retrospectively analysed 144 patients with NMOSD and 2892 with MS followed at a neuroimmunology clinic between 2015 and 2023. Demographic, clinical, and comorbidity data were systematically extracted from electronic records.
RESULTS: Comorbidity profiles differed significantly between groups. NMOSD patients more frequently had systemic lupus erythematosus (3.5% vs 0.1%, p < 0.01), diabetes mellitus (12.5% vs 4.5%, p < 0.01), and dyslipidemia (7.6% vs 3.5%, p = 0.012). A trend toward higher prevalence of Behçet's disease was observed (1.4% vs 0.2%, p = 0.052). In contrast, depression/anxiety (20.1% vs 12.5%, p = 0.025), restless legs syndrome (5.6% vs 1.4%, p = 0.029) were significantly more common in MS.
CONCLUSION: NMOSD and MS differ substantially in their comorbidity signatures.
OBJECTIVE: To compare the prevalence and distribution of systemic, metabolic, cardiovascular, and neuropsychiatric comorbidities in patients with NMOSD and MS.
METHODS: We retrospectively analysed 144 patients with NMOSD and 2892 with MS followed at a neuroimmunology clinic between 2015 and 2023. Demographic, clinical, and comorbidity data were systematically extracted from electronic records.
RESULTS: Comorbidity profiles differed significantly between groups. NMOSD patients more frequently had systemic lupus erythematosus (3.5% vs 0.1%, p < 0.01), diabetes mellitus (12.5% vs 4.5%, p < 0.01), and dyslipidemia (7.6% vs 3.5%, p = 0.012). A trend toward higher prevalence of Behçet's disease was observed (1.4% vs 0.2%, p = 0.052). In contrast, depression/anxiety (20.1% vs 12.5%, p = 0.025), restless legs syndrome (5.6% vs 1.4%, p = 0.029) were significantly more common in MS.
CONCLUSION: NMOSD and MS differ substantially in their comorbidity signatures.